Female Sexual Dysfunction Treatment Market Growth, Size, Trends, Demand and Future Outlook
Female Sexual Dysfunction Treatment Market Size- By Type, By Indication, By Age- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Apr-2024 | Report ID: PHAR2407 | Pages: 1 - 238 | Formats*: |
| Category : Pharmaceutical | |||
Female Sexual Dysfunction Treatment Market Introduction and Overview
According to SPER Market Research, the Global Female Sexual Dysfunction Treatment Market is estimated to reach USD XX Billion by 2033 with a CAGR of XX%.
The report includes an in-depth analysis of the Global Female Sexual Dysfunction Treatment Market, including market size and trends, product mix, applications, and supplier analysis. Female sexual dysfunction refers to a variety of problems that can significantly affect a woman's quality of life and general well-being. It can cause emotional pain, strained relationships, and low self-esteem. Recognising the significance of tackling this issue, the healthcare industry has seen the development of multiple treatment solutions that address various aspects of female sexual dysfunction.
- January 2023: Mayne Pharma Group Limited has announced the completion of its exclusive product licencing agreement with TherapeuticsMD, Inc. Mayne Pharma Group Limited has acquired a portfolio of three patent-protected new women's health drugs, including IMVEXXY, through the exclusive licence arrangement.
- September 2022: Freya Pharma Solutions obtained early scientific guidance from the European Medicines Agency (EMA) on its forthcoming phase 3 clinical trial to confirm Lybrido's efficacy in women suffering from FSIAD.
Market Opportunities and Challenges
The female sexual dysfunction therapy industry has many opportunities for growth and expansion. Increased investment in R&D activities has the potential to lead to the launch of new treatment modalities and therapeutic approaches. Furthermore, the growing emphasis on personalised medicine and the creation of customised treatment solutions adapted to individual needs may open up new opportunities for market participants. Collaborations between pharmaceutical corporations and healthcare professionals can also aid in the development of novel and complete treatment solutions.
Increased awareness of female sexual dysfunctions among women is likely to drive market growth over the forecast period. The International Society for Sexual Medicine is a key player in promoting evidence-based scientific advances in sexual medicine around the world, addressing both male and female practitioners and patients. The organization's goal is to increase sexual health awareness, understanding, and support through improved communication and marketing. The "Right to Desire" campaign, funded by Sprout Pharmaceuticals, teaches women about sexual dysfunction. Similarly, the Find My Spark programme, developed by W2O Group and the American Sexual Health Association, promotes frank discussions about sexual issues, which aids market growth.
Despite the good market forecast, certain obstacles limit the growth of the female sexual dysfunction therapy industry. One of the most significant obstacles is the stigma associated with addressing sexual health issues, which frequently inhibits women from getting necessary care. Limited access to healthcare services and high treatment costs are further impediments to market expansion, especially in underdeveloped countries. Furthermore, the lack of globally accepted diagnostic criteria and treatment protocols hinders consistent and standardised treatment techniques.
Market Competitive Landscape
The female sexual dysfunction therapy market has a competitive landscape that includes both established pharmaceutical corporations and developing players. Key market participants are focusing on product innovation, strategic alliances, and mergers and acquisitions to obtain a competitive advantage. Furthermore, the release of generic copies of existing pharmaceuticals, as well as the development of cost-effective treatment choices, is driving up market competitiveness. The major key players in the Global Female Sexual Dysfunction Treatment Market are: AMAG Pharmaceuticals Inc., Apricus Biosciences, Inc., Cipla Inc., Duchesnay Inc., Emotional Brain BV, GlaxoSmithKline, Plc, Merck & Co., Inc., Novo Nordisk AS, Pfizer, Inc., Pivot Pharmaceuticals Inc., Sprout Pharmaceuticals, Inc, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type, By Indication, By Age |
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America |
| Companies Covered | AMAG Pharmaceuticals Inc., Apricus Biosciences, Inc., Cipla Inc., Duchesnay Inc., Emotional Brain BV, GlaxoSmithKline, Plc, Merck & Co., Inc., Novo Nordisk AS, Pfizer, Inc., Pivot Pharmaceuticals Inc., Sprout Pharmaceuticals, Inc, Others. |
COVID-19 Impact on Global Female Sexual Dysfunction Treatment Market
The COVID-19 pandemic has had varying effects on the female sexual dysfunction treatment market. While the initial part of the pandemic disrupted healthcare services and reduced patient visits, there has been a greater emphasis on telehealth and virtual consultations. The epidemic has highlighted the need of addressing sexual health concerns and prompted the creation of remote treatment options. Economic uncertainty and difficulty in allocating healthcare resources have had an impact on market growth.
Key Target Audience:
- Healthcare Providers (Gynecologists, Urologists, Endocrinologists, Psychiatrists, etc.)
- Pharmaceutical Companies and Drug Manufacturers
- Women's Health Organizations and Advocacy Groups
- Sexual Health Clinics and Centers
- Mental Health Professionals (Psychologists, Counselors, Therapists, etc.)
- Patients and Consumers
- Others
Our in-depth analysis of the Female Sexual Dysfunction Treatment Market includes the following segments:
| By Type: |
|
| By Indication: |
|
| By Age: |
|
Key Topics Covered in the Report:
- Global Female Sexual Dysfunction Treatment Market Size (FY’2024-FY’2033)
- Overview of Global Female Sexual Dysfunction Treatment Market
- Segmentation of Global Female Sexual Dysfunction Treatment Market By Type (Counselling and Behavioral Therapy, Medication, Others)
- Segmentation of Global Female Sexual Dysfunction Treatment Market By Indication (Arousal Disorder, Female Orgasmic Disorder, Hypoactive Sexual Desire Disorder (HSDD), Penetration (Sexual Pain) Disorder, Others)
- Segmentation of Global Female Sexual Dysfunction Treatment Market By Age (18-30 Years, 30-45 Years, Above 45 Years)
- Statistical Snap of Global Female Sexual Dysfunction Treatment Market
- Expansion Analysis of Global Female Sexual Dysfunction Treatment Market
- Problems and Obstacles in Global Female Sexual Dysfunction Treatment Market
- Competitive Landscape in the Global Female Sexual Dysfunction Treatment Market
- Impact of COVID-19 and Demonetization on Global Female Sexual Dysfunction Treatment Market
- Details on Current Investment in Global Female Sexual Dysfunction Treatment Market
- Competitive Analysis of Global Female Sexual Dysfunction Treatment Market
- Prominent Players in the Global Female Sexual Dysfunction Treatment Market
- SWOT Analysis of Global Female Sexual Dysfunction Treatment Market
- Global Female Sexual Dysfunction Treatment Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Global Female Sexual Dysfunction Treatment Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.4. Heat Map Analysis5.3.5. Competitive rivalry
6. Competitive Landscape
6.1. Global Female Sexual Dysfunction Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Female Sexual Dysfunction Treatment Market
7. Global Female Sexual Dysfunction Treatment Market, By Type (USD Million) 2020-2033
7.1. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Type, 2020-20267.2. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Type, 2027-20337.3. Counselling and Behavioral Therapy7.4. Medication7.4.1. Hormonal Therapy7.4.2. Non-Hormonal Therapy7.5. Others
8. Global Female Sexual Dysfunction Treatment Market, By Indication (USD Million) 2020-2033
8.1. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Indication, 2020-20268.2. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Indication, 2027-20338.3. Arousal Disorder8.4. Female Orgasmic Disorder8.5. Hypoactive Sexual Desire Disorder (HSDD)8.6. Penetration (Sexual Pain) Disorder8.7. Others
9. Global Female Sexual Dysfunction Treatment Market, By Age (USD Million) 2020-2033
9.1. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Age, 2020-20269.2. Global Female Sexual Dysfunction Treatment Market Size, Share and Forecast, By Age, 2027-20339.3. 18-30 Years9.4. 30-45 Years9.5. Above 45 Years
10. Global Female Sexual Dysfunction Treatment Market Forecast, 2020-2033 (USD Million)
10.1. Global Female Sexual Dysfunction Treatment Market Size and Market Share
11. Global Female Sexual Dysfunction Treatment Market, By Region, 2020-2033 (USD Million)
11.1. Global Female Sexual Dysfunction Treatment Market Size and Market Share By Region (2020-2026)11.2. Global Female Sexual Dysfunction Treatment Market Size and Market Share By Region (2027-2033)11.3. Asia-Pacific11.3.1. Australia11.3.2. China11.3.3. India11.3.4. Japan11.3.5. South Korea11.3.6. Rest of Asia-Pacific11.4. Europe11.4.1. France11.4.2. Germany11.4.3. Italy11.4.4. Spain11.4.5. United Kingdom11.4.6. Rest of Europe11.5. Middle East and Africa11.5.1. Kingdom of Saudi Arabia11.5.2. United Arab Emirates11.5.3. Qatar11.5.4. South Africa11.5.5. Egypt11.5.6. Morocco11.5.7. Nigeria11.5.8. Rest of Middle East & Africa11.6. North America11.6.1. Canada11.6.2. Mexico11.6.3. United States11.7. Latin America11.7.1. Argentina11.7.2. Brazil11.7.3. Rest of Latin America
12. Company Profile
12.1. AMAG Pharmaceuticals Inc12.1.1. Company details12.1.2. Financial outlook12.1.3. Product summary12.1.4. Recent developments12.2. Apricus Biosciences, Inc12.2.1. Company details12.2.2. Financial outlook12.2.3. Product summary12.2.4. Recent developments12.3. Cipla Inc12.3.1. Company details12.3.2. Financial outlook12.3.3. Product summary12.3.4. Recent developments12.4. Duchesnay Inc12.4.1. Company details12.4.2. Financial outlook12.4.3. Product summary12.4.4. Recent developments12.5. Emotional Brain BV12.5.1. Company details12.5.2. Financial outlook12.5.3. Product summary12.5.4. Recent developments12.6. GlaxoSmithKline, Plc12.6.1. Company details12.6.2. Financial outlook12.6.3. Product summary12.6.4. Recent developments12.7. Merck & Co., Inc12.7.1. Company details12.7.2. Financial outlook12.7.3. Product summary12.7.4. Recent developments12.8. Novo Nordisk AS12.8.1. Company details12.8.2. Financial outlook12.8.3. Product summary12.8.4. Recent developments12.9. Pfizer, Inc12.9.1. Company details12.9.2. Financial outlook12.9.3. Product summary12.9.4. Recent developments12.10. Pivot Pharmaceuticals Inc12.10.1. Company details12.10.2. Financial outlook12.10.3. Product summary12.10.4. Recent developments12.11. Sprout Pharmaceuticals, Inc.12.11.1. Company details12.11.2. Financial outlook12.11.3. Product summary12.11.4. Recent developments12.12. Others
13. List of Abbreviations
14. Reference Links
15. Conclusion
16. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Female Sexual Dysfunction Treatment Market is projected to reach USD XX billion by 2033, growing at a CAGR of XX% during the forecast period.
Female Sexual Dysfunction Treatment Market grew in Market size from 2022. The Market is expected to reach USD XX billion by 2033, at a CAGR of XX% during the forecast period.
Female Sexual Dysfunction Treatment Market CAGR of XX% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Female Sexual Dysfunction Treatment Market size is USD XX billion from 2024 to 2033.
Female Sexual Dysfunction Treatment Market Segment is covered By Type, By Indication, By Age.
The North America is anticipated to have the highest Market share in the Female Sexual Dysfunction Treatment Market.
The key players in the Market include Companies Covered AMAG Pharmaceuticals Inc., Apricus Biosciences, Inc., Cipla Inc., Duchesnay Inc., Emotional Brain BV, GlaxoSmithKline, Plc, Merck & Co., Inc., Sprout Pharmaceuticals, Inc, Others.
Female sexual dysfunction refers to a variety of problems that can significantly affect a woman's quality of life and general well-being.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
